Loading
A cavity-imaging dye used during breast lumpectomy to spot leftover tumour before the operation ends, reducing second surgeries.
Pegulicianine is a PEGylated, quenched fluorescent dye that is cleaved by cathepsins and matrix metalloproteinases abundant in tumour and tumour-associated cells. When the lumpectomy cavity is scanned with the Lumicell direct visualisation system after standard excision, activated dye reveals residual cancer so the surgeon can remove it before closing. In the INSITE trial (NEJM Evidence 2023) residual tumour was found in 7.6% of patients after standard lumpectomy, with a sensitivity of 49% and specificity of 86%, and some re-excisions were avoided. The FDA approved it in April 2024 as an adjunct for intraoperative detection of residual breast cancer; anaphylaxis is a recognised risk. Its modest sensitivity means it complements rather than replaces margin pathology. Pegulicianine aims to reduce the second operations that follow many breast-conserving surgeries.
PEGylated quenched dye cleaved by cathepsins and MMPs abundant in tumour and tumour-associated cells, fluorescing in the lumpectomy cavity to reveal residual cancer.
1.Pegulicianine slips into a pocket on its target.
Intraoperative imaging agent for breast lumpectomy margin assessment, bundled into the surgical payment; hospital outpatient use had a pass-through payment code after approval.
Bundled into the surgical claim; some plans consider it investigational.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · Medicare.gov: Inpatient hospital care (Part A). Not medical or financial advice; verify with your plan.
Sources: NICE search: pegulicianine. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2024 | Fluorescence imaging in adults with breast cancer as an adjunct for intraoperative detection of residual cancer after lumpectomy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pegulicianine" OR ABSTRACT:"Pegulicianine" OR TITLE:"Lumisight" OR ABSTRACT:"Lumisight") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pegulicianine, not a curated reading list.
Shares Optical & fluorescence imaging, Fluorescence-guided surgery, Multiple myeloma and the tag diagnostic.
Shares Optical & fluorescence imaging, Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath), Fluorescence-guided surgery and the tag diagnostic.
Shares Multiple myeloma and the tag diagnostic.
Shares HR-positive / HER2-negative breast cancer and the tag diagnostic.
Shares HR-positive / HER2-negative breast cancer and the tag diagnostic.
Shares Optical & fluorescence imaging, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Optical & fluorescence imaging, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath), Fluorescence-guided surgery.